HUM vs PHG vs CVS Stock Comparison

Humana, Koninklijke Philips and Cvs Health Prices as of Nov 13, 2026 Peers: Industry group
HUM Humana Inc
$450.46 +5.4% 1M +90.3% 1Y
Market cap
$55.42B
P/E
44.5x
Revenue (TTM)
$154.19B
Div. yield
–
Managed Care Healthcare
3 wins
PHG Koninklijke Philips Nv
$30.35 +21.4% 1M +4.9% 1Y
Market cap
$28.63B
P/E
15.0x
Revenue (TTM)
$30.13B
Div. yield
–
Diagnostic Equipment Healthcare
5 wins
CVS CVS HEALTH Corp
$89.33 -1.2% 1M +12.7% 1Y
Market cap
$113.51B
P/E
10.3x
Revenue (TTM)
$420.61B
Div. yield
–
Managed Care Healthcare
3 wins

Head to Head

11 decided of 12

Koninklijke Philips leads on 5 of the 12 questions below (Koninklijke Philips 5, Cvs Health 3, Humana 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionHUMPHGCVSLeader
Larger companyMarket capitalisation $55.42B $28.63B $113.51B CVS
Cheaper on earningsLower P/E, profitable companies only 44.5x 15.0x 10.3x CVS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 50.2x 15.3x 10.2x CVS
Faster revenue growthRevenue growth, trailing twelve months +22.0% +53.4% +6.7% PHG
More profitableNet margin, trailing twelve months 0.8% 6.3% 2.6% PHG
Better return on capitalReturn on invested capital 5.5% 12.1% 9.7% PHG
Less leveragedLower net debt / EBITDA -3.9x 1.7x 2.3x HUM
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +90.3% +4.9% +12.7% HUM
Better 5-year returnAnnualised price return, 5 years +0.2%/yr -8.6%/yr -1.0%/yr HUM
Less volatileAnnualised volatility, 1 year 47.3% 29.5% 35.1% PHG
Higher overall scoreMean of the five percentile scores vs peers 55/100 80/100 72/100 PHG

Percentile Scorecard

HUMPHGCVS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisHUMPHGCVS
Valuation 69 #9 of 27 98 #6 of 243 100 #1 of 27
Growth 44 #15 of 26 99 #3 of 228 80 #6 of 26
Profitability 48 #14 of 26 92 #18 of 222 84 #5 of 26
Financial Health 80 #6 of 26 30 #175 of 248 24 #20 of 26
Shareholder Returns 35 #12 of 18 81 #31 of 158 71 #6 of 18
Overall 55 80 72
  • HUM ranked among 27 companies in Healthcare Payers and Distributors
  • PHG ranked among 252 companies in Medical Devices and Diagnostics
  • CVS ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodHUMPHGCVSSPY
1 month +5.4%+21.4%-1.2% -2.0%
3 months +15.6%+11.3%-8.1% -2.8%
6 months +47.6%+20.3%-6.8% +2.0%
Year to date +75.9%+12.1%+12.6% +10.6%
1 year +90.3%+4.9%+12.7% +12.2%
3 years -10.3%+45.8%+30.4% +68.1%
3 years, per year -3.5%+13.4%+9.3% +18.9%
5 years +1.1%-36.3%-5.0% +61.4%
5 years, per year +0.2%-8.6%-1.0% +10.1%
10 years +133.2%+4.2%+19.0% +248.5%
10 years, per year +8.8%+0.4%+1.8% +13.3%

Risk

MeasureHUMPHGCVSSPY
Volatility, 1Y 47.3%29.5%35.1% 13.6%
Downside volatility, 1Y 50.6%27.6%38.8% 13.9%
Beta vs S&P 500, 1Y 0.520.84-0.05 1.00
Return / volatility, 1Y 1.910.170.36 0.90
Max drawdown, 5Y -70.9%-72.2%-60.5% -25.4%
From 52-week high 0.0%-7.8%-19.2% -3.2%
52-week high $450.46$32.91$110.55 $779.14
52-week low $163.67$23.81$70.08 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleHUMPHGCVS
P/E now vs peer median 43.4xmedian 25.2x 15.1xmedian 26.5x 10.4xmedian 25.2x
P/S now vs peer median 0.4xmedian 0.4x 1.0xmedian 2.7x 0.3xmedian 0.4x
EV/EBITDA now vs peer median 13.3xmedian 14.5x 8.5xmedian 18.4x 8.2xmedian 14.5x
P/FCF now vs peer median 17.2xmedian 16.5x 5.6xmedian 25.4x 7.3xmedian 16.5x
P/B now vs peer median 2.9xmedian 2.7x 2.2xmedian 2.5x 1.4xmedian 2.7x
PEG now vs peer median -1.73median 1.72 0.22median 0.98 1.22median 1.72

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsHUMPHGCVS
Revenue $154.19B $30.13B $420.61B
Gross profit $20.06B $16.13B $186.06B
Operating income $2.38B $2.79B $15.06B
Net income $1.26B $1.45B $11.09B
Free cash flow $3.14B $5.23B $15.57B
R&D – $1.99B –
EPS (diluted) $10.23 $1.98 $8.55
Cash & equivalents $6.94B $3.12B $11.74B
Total debt $12.92B $10.22B $60.68B
Shares (diluted) 121.83M 962.50M 1.29B
Enterprise value -$35.43B $16.90B $62.27B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricHUMPHGCVS
P/E 43.4x 15.1x 10.4x
P/FCF 17.2x 5.6x 7.3x
P/Operating cash flow 14.5x 8.2x 6.1x
P/S 0.4x 1.0x 0.3x
P/B 2.9x 2.2x 1.4x
P/Tangible book 2.9x 2.8x 2.0x
EV/EBITDA 13.3x 8.5x 8.2x
EV/EBIT 17.6x 13.0x 10.6x
EV/Revenue 0.3x 1.2x 0.4x
EV/FCF 13.3x 6.9x 10.3x
EV/Operating cash flow 11.2x 10.2x 8.6x
PEG (3Y EPS CAGR) -1.73 0.22 1.22

Growth

14 metrics
MetricHUMPHGCVS
Revenue growth (1Y) 22.0% 53.4% 6.7%
Revenue CAGR (3Y) 14.6% 15.1% 6.5%
Gross profit growth (1Y) 6.2% 76.3% 5.3%
Gross profit CAGR (3Y) 3.4% 4.0% 10.9%
Operating income growth (1Y) -19.8% 49.6% 206.4%
Operating income CAGR (3Y) -19.0% 337.8% 2.4%
Net income growth (1Y) -2.9% 444.3% 2,369%
Net income CAGR (3Y) -25.2% 45.2% 8.6%
EPS growth (1Y) -4.3% 177.7% 2,213%
EPS CAGR (3Y) -25.1% 69.9% 8.5%
Operating cash flow growth (1Y) 82.4% 154.0% 105.4%
Operating cash flow CAGR (3Y) -14.6% 34.9% 9.9%
Free cash flow growth (1Y) 102.9% 74.5% 147.4%
Free cash flow CAGR (3Y) -14.3% 35.7% 11.3%

Profitability

14 metrics
MetricHUMPHGCVS
Gross margin 13.0% 53.5% 44.2%
EBITDA margin 2.0% 14.1% 4.7%
Operating margin 1.5% 9.2% 3.6%
Pretax margin 1.1% 8.7% 2.9%
Net margin 0.8% 6.3% 2.6%
FCF margin 2.0% 17.4% 3.7%
Operating cash flow margin 2.4% 11.8% 4.4%
Return on equity 6.6% 13.2% 13.8%
Return on assets 2.2% 5.5% 4.3%
Return on invested capital 5.5% 12.1% 9.7%
Return on capital employed 7.2% 12.6% 9.2%
Asset turnover 2.7x 1.0x 1.6x
Cash conversion (OCF / net income) 3.0x 2.4x 1.7x
Stock comp / revenue 0.1% 0.5% 0.2%

Financial Health

11 metrics
MetricHUMPHGCVS
Debt / assets 22.4% 32.2% 23.5%
Debt / equity 0.7x 0.8x 0.8x
Net debt / EBITDA -3.9x 1.7x 2.3x
Debt / FCF 4.1x 2.0x 3.9x
Liabilities / assets 67.0% 58.7% 68.7%
Equity / assets 33.0% 41.3% 31.3%
Interest coverage 3.2x 6.5x 4.9x
Current ratio 1.6x 1.3x 0.9x
Quick ratio 1.2x 0.8x 0.8x
Cash ratio 1.0x 0.4x 0.2x
Altman Z-score 4.75 – 2.51

Shareholder Returns

7 metrics
MetricHUMPHGCVS
Dividend yield 0.8% 3.3% 3.0%
Net buyback yield 0.3% -0.7% -0.4%
Shareholder yield 1.1% 2.5% 2.6%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusHUMPHGCVS
Forward P/E 50.2xFY2026 15.3xFY2026 10.2xFY2026
EPS, next fiscal year $8.98FY2026 $1.99FY2026 $8.80FY2026
EPS growth, next FY -47.6%FY2026 +7.0%FY2026 +30.4%FY2026
EPS growth, the year after +95.0% -10.6% +1.1%
Revenue, next fiscal year $167.02BFY2026 $21.44BFY2026 $431.16BFY2026
Revenue growth, next FY +28.8%FY2026 +0.9%FY2026 +7.2%FY2026
Revenue growth, the year after +11.4% -7.8% -5.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersHUMPHGCVS
Held by institutions 98.6% 5.4% 89.1%
Institutions holding 930 365 2,074
Change in shares held, QoQ +2.7% +0.8% +3.5%
Institutions buying 560 267 1,103
Institutions selling 267 76 733
Buyers to sellers 2.10 3.51 1.50

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

HUMPHGCVS
HUM 1.00 0.02 0.52
PHG 0.02 1.00 -0.08
CVS 0.52 -0.08 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, HUM, PHG and CVS?

Cvs Health (CVS) is the largest by market capitalisation: Humana (HUM) $55.42B, Koninklijke Philips (PHG) $28.63B, Cvs Health (CVS) $113.51B.

Which stock is cheaper, HUM, PHG and CVS?

Cvs Health (CVS) trades on the lowest price-to-earnings ratio (Humana (HUM) 44.5x, Koninklijke Philips (PHG) 15.0x, Cvs Health (CVS) 10.3x). On next year's consensus earnings, Cvs Health (CVS) is cheapest (Humana (HUM) 50.2x, Koninklijke Philips (PHG) 15.3x, Cvs Health (CVS) 10.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Koninklijke Philips (PHG) grew revenue fastest over the trailing twelve months: Humana (HUM) +22.0%, Koninklijke Philips (PHG) +53.4%, Cvs Health (CVS) +6.7%.

Which company is more profitable?

Koninklijke Philips (PHG) has the highest net margin (Humana (HUM) 0.8%, Koninklijke Philips (PHG) 6.3%, Cvs Health (CVS) 2.6%). On return on invested capital, Koninklijke Philips (PHG) leads (Humana (HUM) 5.5%, Koninklijke Philips (PHG) 12.1%, Cvs Health (CVS) 9.7%).

Which stock has performed better?

Over the past year Humana (HUM) returned the most: Humana (HUM) +90.3%, Koninklijke Philips (PHG) +4.9%, Cvs Health (CVS) +12.7%. Over five years, Humana (HUM) compounded fastest (Humana (HUM) +0.2%/yr, Koninklijke Philips (PHG) -8.6%/yr, Cvs Health (CVS) -1.0%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (Humana (HUM) 47.3%, Koninklijke Philips (PHG) 29.5%, Cvs Health (CVS) 35.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, HUM, PHG and CVS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.